These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32130630)

  • 1. Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum.
    Janssens J; Vermeiren Y; van Faassen M; van der Ley C; Kema IP; De Deyn PP
    Neurochem Res; 2020 May; 45(5):1191-1201. PubMed ID: 32130630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with
    Barschke P; Oeckl P; Steinacker P; Al Shweiki MR; Weishaupt JH; Landwehrmeyer GB; Anderl-Straub S; Weydt P; Diehl-Schmid J; Danek A; Kornhuber J; Schroeter ML; Prudlo J; Jahn H; Fassbender K; Lauer M; van der Ende EL; van Swieten JC; Volk AE; Ludolph AC; Otto M;
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):503-511. PubMed ID: 32132225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation.
    Katzeff JS; Bright F; Lo K; Kril JJ; Connolly A; Crossett B; Ittner LM; Kassiou M; Loy CT; Hodges JR; Piguet O; Kiernan MC; Halliday GM; Kim WS
    Sci Rep; 2020 Aug; 10(1):13741. PubMed ID: 32792518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum.
    Wilke C; Preische O; Deuschle C; Roeben B; Apel A; Barro C; Maia L; Maetzler W; Kuhle J; Synofzik M
    J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1270-1272. PubMed ID: 27188986
    [No Abstract]   [Full Text] [Related]  

  • 5. CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrum.
    Morelli C; Tiloca C; Colombrita C; Zambon A; Soranna D; Lafronza A; Solca F; Carelli L; Poletti B; Doretti A; Verde F; Maderna L; Ticozzi N; Ratti A; Silani V
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):63-69. PubMed ID: 31852251
    [No Abstract]   [Full Text] [Related]  

  • 6. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase.
    Oeckl P; Weydt P; Steinacker P; Anderl-Straub S; Nordin F; Volk AE; Diehl-Schmid J; Andersen PM; Kornhuber J; Danek A; Fassbender K; Fliessbach K; ; Jahn H; Lauer M; Müller K; Knehr A; Prudlo J; Schneider A; Thal DR; Yilmazer-Hanke D; Weishaupt JH; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):4-10. PubMed ID: 30224549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis.
    Majumder V; Gregory JM; Barria MA; Green A; Pal S
    BMC Neurol; 2018 Jun; 18(1):90. PubMed ID: 29954341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.
    Wilke C; Pujol-Calderón F; Barro C; Stransky E; Blennow K; Michalak Z; Deuschle C; Jeromin A; Zetterberg H; Schüle R; Höglund K; Kuhle J; Synofzik M
    Clin Chem Lab Med; 2019 Sep; 57(10):1556-1564. PubMed ID: 31251725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.
    Illán-Gala I; Alcolea D; Montal V; Dols-Icardo O; Muñoz L; de Luna N; Turón-Sans J; Cortés-Vicente E; Sánchez-Saudinós MB; Subirana A; Sala I; Blesa R; Clarimón J; Fortea J; Rojas-García R; Lleó A
    Neurology; 2018 Oct; 91(17):e1619-e1628. PubMed ID: 30291183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders.
    Bourbouli M; Rentzos M; Bougea A; Zouvelou V; Constantinides VC; Zaganas I; Evdokimidis I; Kapaki E; Paraskevas GP
    Dement Geriatr Cogn Disord; 2017; 44(3-4):144-152. PubMed ID: 28848086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroanatomical Quantitative Proteomics Reveals Common Pathogenic Biological Routes between Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).
    Iridoy MO; Zubiri I; Zelaya MV; Martinez L; Ausín K; Lachen-Montes M; Santamaría E; Fernandez-Irigoyen J; Jericó I
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.
    Chen Y; Stankovic R; Cullen KM; Meininger V; Garner B; Coggan S; Grant R; Brew BJ; Guillemin GJ
    Neurotox Res; 2010 Aug; 18(2):132-42. PubMed ID: 19921535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis.
    Alarcan H; Chaumond R; Emond P; Benz-De Bretagne I; Lefèvre A; Bakkouche SE; Veyrat-Durebex C; Vourc'h P; Andres C; Corcia P; Blasco H
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34063031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure to ALS-FTD-CSF generates TDP-43 aggregates in glioblastoma cells through exosomes and TNTs-like structure.
    Ding X; Ma M; Teng J; Teng RK; Zhou S; Yin J; Fonkem E; Huang JH; Wu E; Wang X
    Oncotarget; 2015 Sep; 6(27):24178-91. PubMed ID: 26172304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.
    Gaiani A; Martinelli I; Bello L; Querin G; Puthenparampil M; Ruggero S; Toffanin E; Cagnin A; Briani C; Pegoraro E; Sorarù G
    JAMA Neurol; 2017 May; 74(5):525-532. PubMed ID: 28264096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delineating the relationship between amyotrophic lateral sclerosis and frontotemporal dementia: Sequence and structure-based predictions.
    Kumar V; Islam A; Hassan MI; Ahmad F
    Biochim Biophys Acta; 2016 Sep; 1862(9):1742-54. PubMed ID: 27318084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain barrier dysfunction and myelin basic protein in survival of amyotrophic lateral sclerosis with or without frontotemporal dementia.
    Li JY; Cai ZY; Sun XH; Shen DC; Yang XZ; Liu MS; Cui LY
    Neurol Sci; 2022 May; 43(5):3201-3210. PubMed ID: 34826032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UBQLN2/P62 cellular recycling pathways in amyotrophic lateral sclerosis and frontotemporal dementia.
    Fecto F; Siddique T
    Muscle Nerve; 2012 Feb; 45(2):157-62. PubMed ID: 22246868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the caudate nucleus head and its networks in sporadic amyotrophic lateral sclerosis-frontotemporal dementia continuum.
    Masuda M; Senda J; Watanabe H; Epifanio B; Tanaka Y; Imai K; Riku Y; Li Y; Nakamura R; Ito M; Ishigaki S; Atsuta N; Koike H; Katsuno M; Hattori N; Naganawa S; Sobue G
    Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(7-8):571-579. PubMed ID: 27684890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
    Weishaupt JH; Hyman T; Dikic I
    Trends Mol Med; 2016 Sep; 22(9):769-783. PubMed ID: 27498188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.